Current investigations into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are showing promising outcomes in managing obesity and related non-insulin-dependent diabetes. Animal data suggest a distinct https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/